

DESCRIPTION

Source	Mouse myeloma cell line, NS0-derived			
	Rat Neuropilin-2 Gln23-Asp857 (Val809-Asp825 del) Accession # O35276	IEGRDMD	Human IgG ₁ (Pro100-Lys330)	6-His tag
	N-terminus		C-terminus	

N-terminal Sequence No results obtained: Gln23 predicted

Analysis

Structure / Form Disulfide-linked homodimer

Predicted Molecular Mass 120 kDa (monomer)

SPECIFICATIONS

SDS-PAGE 130-150 kDa, reducing conditions

Activity Measured by its binding ability in a functional ELISA. Immobilized Recombinant Rat Neuropilin-2 Fc Chimera at 5 µg/mL (100 µL/well) can bind recombinant human VEGF₁₆₅ in the presence of 2 µg/mL of heparin with an apparent K_d <1nM.

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 200 µg/mL in sterile PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Neuropilin-2 (Nrp2) is a transmembrane glycoprotein that plays an important role in neuronal axon guidance and development of the vascular system (1). Neuropilin-2 is differentially expressed in the developing nervous system (2). It binds to Semaphorins 3B, 3C, and 3F, leading to neuronal growth cone collapse (2-4). This action is important for repulsive axon guidance and accurate axon projection to target fields (4-7). Neuropilin-2 interacts with a range of proteins that regulate cell growth and morphology. It associates with TGF-beta RI and enhances the ability of TGF-beta to induce epithelial mesenchymal transition during tumorigenesis (8). It associates with Integrin α6β1 and promotes α6β1 mediated adhesion to Laminin (9). Neuropilin-2 additionally binds the heparin-binding PIGF-2, HGF, VEGF₁₄₅, and VEGF₁₆₅ (10, 11) and associates with VEGF R1, VEGF R2, and VEGF R3 (12, 13). The presence of Neuropilin-2 on vascular endothelial cells potentiates the angiogenic signaling effects of HGF and VEGF₁₆₅ (11). Semaphorin 3F, however, can block the contribution of Neuropilin-2 to angiogenesis (13). In the vascular system, Neuropilin-2 is predominantly expressed on lymphatic vessel and capillary endothelial cells where it cooperates with VEGF R3 to induce lymphatic sprouting (14, 15). Neuropilin-2 is lost from sympathetic nerve fibers in rheumatoid arthritis (RA) synovium, while a soluble form is elevated in RA synovial fluid (16). Neuropilin-2 is expressed as an approximately 120 kDa molecule that associates into homo-oligomers or hetero-oligomers with Neuropilin-1 (3, 4). It can be polysialylated during dendritic cell maturation to reach sizes as large as 200 kDa (17). Mature rat Neuropilin-2 consists of an 836 amino acid (aa) extracellular domain (ECD) with two CUB domains, two complement factor 5/8-like domains, one MAM domain, and a Ser-Thr rich region, followed by a 25 aa transmembrane segment and a 42 aa cytoplasmic domain (18). Within the ECD, rat Neuropilin-2 shares 93% and 97% aa sequence identity with human and mouse Neuropilin-2, respectively.

References:

1. Parker, M.W. *et al.* (2012) *Biochemistry* **51**:9437.
2. Chen, H. *et al.* (1997) *Neuron* **19**:547.
3. Takahashi, T. *et al.* (1998) *Nat. Neurosci.* **1**:487.
4. Giger, R.J. *et al.* (1998) *Neuron* **21**:1079.
5. Giger, R.J. *et al.* (2000) *Neuron* **25**:29.
6. Chen, H. *et al.* (2000) *Neuron* **25**:43.
7. Claudepierre, T. *et al.* (2008) *Dev. Dyn.* **237**:3394.
8. Grandclement, C. *et al.* (2011) *PLoS ONE* **6**:e20444.
9. Goel, H.L. *et al.* (2012) *J. Cell Sci.* **125**:497.
10. Gluzman-Poltorak, Z. *et al.* (2000) *J. Biol. Chem.* **275**:18040.
11. Sulpice, E. *et al.* (2008) *Blood* **111**:2036.
12. Gluzman-Poltorak, Z. *et al.* (2001) *J. Biol. Chem.* **276**:18688.
13. Favier, B. *et al.* (2006) *Blood* **108**:1243.
14. Yuan, L. *et al.* (2002) *Development* **129**:4797.
15. Xu, Y. *et al.* (2010) *J. Cell Biol.* **188**:115.
16. Fassold, A. *et al.* (2009) *Arthritis Rheum.* **60**:2892.
17. Curreli, S. *et al.* (2007) *J. Biol. Chem.* **282**:30346.
18. Kolodkin, A.L. *et al.* (1997) *Cell* **90**:753.

PRODUCT SPECIFIC NOTICES

This product or the use of this product is covered by U.S. Patents owned by The Regents of the University of California. This product is for research use only and is not to be used for commercial purposes. Use of this product to produce products for sale or for diagnostic, therapeutic or drug discovery purposes is prohibited.

In order to obtain a license to use this product for such purposes, contact The Regents of the University of California. U.S. Patent # 6,054,293, 6,623,738, and other U.S. and international patents pending.